• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Mastitis Market Trends

    ID: MRFR/Pharma/3936-CR
    142 Pages
    Rahul Gotadki
    July 2019

    Mastitis Market Research Report Information by Type (Bovine {Contagious Mastitis, Environmental Mastitis and Opportunist Mastitis} and Human {Non-Infectious Mastitis and Infectious Mastitis}), Treatment (Bovine {Antibiotics and Vaccines} and Human {Pain Relievers and Antibiotics}), End User (Veterinary Centers and Hospital & Clinics) - Forecast till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Mastitis Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Market Trends

    Mastitis Market Trends and Future Forecast

    Changes in how people live, eat, and interact in society have made cancer more widespread. Among various types of cancer, breast cancer is the most common in women globally and ranks second overall. In 2018 alone, there were over 2 million new cases of breast cancer worldwide, as reported by the World Cancer Research Fund. Unfortunately, women who have had breast cancer are at a higher risk of developing mastitis, especially during breastfeeding. The increasing number of breast cancer cases globally is a major factor contributing to the growth of the global mastitis market. For instance, in the United States, the Breast Cancer Research Foundation estimated that 266,120 new cases of invasive breast cancer were diagnosed in women in 2018, making it the most common cancer among American women, second only to skin cancer. The impact of breast cancer is not limited to the United States. In the United Kingdom, breast cancer was responsible for approximately 11,563 deaths in 2016, according to Cancer Research UK. On a global scale, Belgium had the highest rate of breast cancer in women in 2017, with a rate of 113.2 per 10,000 breast cancer cases, as reported by the World Cancer Research Fund International. This trend of increasing breast cancer rates worldwide is directly linked to a rise in mastitis cases. As more women experience breast cancer, the occurrences of mastitis, an inflammation of the breast tissue often associated with breastfeeding, are also on the rise. The connection between breast cancer and mastitis emphasizes the need for effective solutions and treatments for mastitis. Understanding the global trends in breast cancer and its consequences, including mastitis, is crucial for healthcare professionals and researchers working to address the challenges posed by these conditions. The increasing prevalence of breast cancer globally underscores the importance of ongoing efforts to develop better diagnostic tools, preventive measures, and treatment options for mastitis and related complications.

    Market Summary

    As per Market Research Future Analysis, the Mastitis Market was valued at USD 23.63 Billion in 2023 and is projected to grow to USD 53.64 Billion by 2032, with a CAGR of 16.73% from 2024 to 2032. The condition primarily affects nursing women and dairy cattle, leading to significant health issues and economic losses in livestock production. Recent innovations include Danone's probiotic supplement Almimama and Zoetis's Protivity® vaccine, aimed at reducing mastitis incidence. The market is driven by rising disease prevalence, product innovations, and increased awareness among dairy producers. However, challenges such as antibiotic resistance and diagnostic difficulties may hinder growth.

    Key Market Trends & Highlights

    The Mastitis Market is witnessing significant growth driven by various factors.

    • Market Size in 2023: USD 23.63 Billion
    • Projected Market Size by 2032: USD 53.64 Billion
    • CAGR from 2024 to 2032: 16.73%
    • Major innovations include Danone's Almimama and Zoetis's Protivity®

    Market Size & Forecast

    2023 Market Size USD 23.63 Billion
    2024 Projected Market Size USD 36.14 Billion
    2032 Projected Market Size USD 53.64 Billion
    CAGR (2024-2032) 16.73%

    Major Players

    Bayer AG, Zoetis Inc., Boehringer Ingelheim GmbH, Merck Co. & Inc., Pfizer Inc.

    Market Trends

    The increasing prevalence of mastitis in dairy herds underscores the urgent need for effective management strategies to enhance animal welfare and ensure the sustainability of dairy production.

    U.S. Department of Agriculture (USDA)

    Mastitis Market Market Drivers

    Market Growth Projections

    The Global Mastitis Market Industry is poised for substantial growth, with projections indicating a compound annual growth rate (CAGR) of 8.12% from 2025 to 2035. This growth trajectory suggests a robust demand for innovative solutions in mastitis management, driven by factors such as rising dairy consumption and advancements in treatment technologies. The market's expansion reflects the increasing recognition of mastitis as a critical issue affecting dairy production and profitability. As stakeholders across the industry respond to these challenges, the market is likely to witness significant investments and developments in the coming years.

    Growing Focus on Animal Welfare

    The increasing emphasis on animal welfare is reshaping the Global Mastitis Market Industry. Consumers are becoming more conscious of the ethical treatment of animals, which drives dairy producers to adopt practices that ensure the health and well-being of their livestock. This focus on welfare includes the implementation of effective mastitis management strategies, as healthy animals are essential for sustainable production. As the market evolves, producers who prioritize animal welfare are likely to gain a competitive edge, further stimulating demand for mastitis-related products and services.

    Government Initiatives and Support

    Government initiatives aimed at improving animal health and welfare are pivotal in shaping the Global Mastitis Market Industry. Various countries are implementing policies that promote research and development in mastitis management, alongside funding programs for farmers to access better veterinary care. These initiatives not only enhance awareness of mastitis but also encourage the adoption of best practices in dairy farming. As governments recognize the economic implications of mastitis, their support is likely to foster innovation and investment in the sector, contributing to sustained market growth.

    Increasing Demand for Dairy Products

    The global surge in demand for dairy products is a significant factor influencing the Global Mastitis Market Industry. As consumer preferences shift towards dairy consumption, the pressure on dairy farmers to maintain high production levels intensifies. This demand creates an urgent need for effective mastitis management solutions to ensure optimal milk quality and quantity. With projections indicating that the market will grow to 85.3 USD Billion by 2035, the dairy sector is likely to invest heavily in mastitis prevention and treatment strategies, thereby driving market expansion.

    Advancements in Diagnostic Technologies

    Technological innovations in the diagnosis of mastitis are transforming the Global Mastitis Market Industry. Enhanced diagnostic tools, such as molecular techniques and rapid testing methods, facilitate early detection and treatment of mastitis, thereby improving herd health and productivity. These advancements enable farmers to monitor their cattle more effectively, leading to timely interventions that can minimize economic losses. As the industry moves towards more precise and efficient diagnostic solutions, the demand for these technologies is expected to surge, contributing to the overall growth of the market.

    Rising Incidence of Mastitis in Dairy Cattle

    The increasing prevalence of mastitis among dairy cattle is a primary driver of the Global Mastitis Market Industry. In 2024, the market is valued at 36.1 USD Billion, reflecting the urgent need for effective treatment and prevention strategies. Mastitis not only affects milk production but also poses significant economic challenges for dairy farmers. The disease can lead to reduced milk yield and quality, which in turn impacts profitability. As awareness of mastitis management grows, investments in veterinary care and innovative treatments are likely to rise, further propelling market growth.

    Market Segment Insights

    Regional Insights

    Key Companies in the Mastitis Market market include

    Industry Developments

      • A new Biological Development Centre (BDC) at Boehringer Ingelheim's research development locations in Biberach, Germany, was revealed in June 2018 with a 230-million-euro investment. The BDC will be the company's first BDC.
      • Tavocept, an experimental novel medication developed by BioNumerik Pharmaceuticals, was approved by the Food and Drug Administration in June 2017 for use in both cancer and non-oncology purposes.
      • Keytruda, developed by Merck & Co., was authorized by the FDA in May 2017 to treat adult and pediatric individuals with recently treated advanced or metastatic or metastatic solid tumors with high microsatellite instability (MSI-H) mismatch repair deficiency.

    Future Outlook

    Mastitis Market Future Outlook

    The Global Mastitis Market is projected to grow at 8.12% CAGR from 2024 to 2032, driven by advancements in treatment technologies and increasing dairy production.

    New opportunities lie in:

    • Develop innovative mastitis detection devices using AI and IoT technologies.
    • Expand product lines to include organic and antibiotic-free treatment options.
    • Invest in educational programs for farmers on mastitis prevention and management.

    By 2035, the Mastitis Market is expected to achieve substantial growth, reflecting evolving industry standards and consumer demands.

    Market Segmentation

    Report Overview

    Recent Developments
    • A new Biological Development Centre (BDC) at Boehringer Ingelheim's research development locations in Biberach, Germany, was revealed in June 2018 with a 230-million-euro investment. The BDC will be the company's first BDC.
    • Tavocept, an experimental novel medication developed by BioNumerik Pharmaceuticals, was approved by the Food and Drug Administration in June 2017 for use in both cancer and non-oncology purposes.
    • Keytruda, developed by Merck & Co., was authorized by the FDA in May 2017 to treat adult and pediatric individuals with recently treated advanced or metastatic or metastatic solid tumors with high microsatellite instability (MSI-H) mismatch repair deficiency.

    Market Segmentation

    Mastitis Market, by Type
    • Bovine
    • Contagious Mastitis
    • Environmental Mastitis
    • Opportunist Mastitis
    • Human
    • Non-Infectious Mastitis
    • Infectious Mastitis
    Mastitis Market, by Region
    • Americas
    • North America
    • US
    • Canada
    • Latin America
    • Europe
    • Western Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Saudi Arabia
    • United Arab Emirates
    • Kuwait
    • Oman
    • Qatar
    • Rest of Middle East
    Mastitis Market, by End User
    • Veterinary Centers
    • Hospital & Clinics
    Mastitis Market, by Treatment
    • Bovine
    • Antibiotics
    • Vaccines
    • Human
    • Pain Relievers
    • Antibiotics

    Report Scope

    Attribute/Metric Details
    Market Size 2023 23.63 (USD Billion)
    Market Size 2024 36.14 (USD Billion)
    Market Size 2032 53.64 (USD Billion)
    Compound Annual Growth Rate (CAGR) 16.73 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2018-2022
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Bayer AG (Germany), Oncothyreon Inc (US), OncoGenex (US), Apthera Inc. (UK), Zoetis Inc. (US), Boehringer Ingelheim GmbH (Germany), Merck Co. & Inc. (US), Astellas Pharma Inc. (Japan), Pfizer Inc. (US), Novartis AG (Switzerland), Sanofi SA (France), and F. Hoffmann-La Roche AG (Switzerland).
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers ·  Rising cases of breast cancer Increasing rate of pregnancy ·  Unhygienic barn conditions causing contagious mastitis in bovines

     

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    At what CAGR is the mastitis market projected to grow in the forecast period (2024-2032)?

    Mastitis market projected to grow at approximately 16.73% CAGR during the assessment period (2024-2032).

    How much is the mastitis market worth in the future?

    The valuation of the mastitis market is estimated to increase to USD 53.64 Bn by the end of 2032.

    What are the major tailwinds pushing the growth of the global mastitis market?

    Increasing need for better treatments and government funding support for R&D are major tailwinds pushing the growth of the global mastitis market.

    Which region holds the largest share in the global mastitis market?

    North America holds the largest share in the global mastitis market, followed by Europe and the Asia Pacific, respectively.

    Who are the top players in the global mastitis market?

    Novartis AG (Switzerland), Pfizer (U.S.), Oncogenex (U.S.), BioNumerik Pharmaceuticals (U.S.), Apthera Inc. (U.K), Oncothyreon Inc. (US), Bipar Sciences (U.S.), Astellas (Japan), Puma Biotechnology (U.S.), Eli Lilly and Company (U.S.), Sanofi S.A. (U.S.), AstraZeneca (UK), GlaxoSmithKline (U.K), F. Hoffmann-La Roche (Switzerland), Genentech (U.S), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries (Israel), Gilead Sciences, Inc. (U.S.), and Accord Healthcare, Inc. (U.S.), are some of the top players operating in the global mastitis market.

    1. '1 Report Prologue
      1. Definition
      2. Scope of the Study
      3. Research Objective
    2. Assumptions & Limitations
      1. Assumptions
        1. Limitations
        2. Market Structure
      2. Primary Research Methodology
      3. Secondary Research Methodology
      4. Market Size Estimation
      5. Forecast Model
      6. Introduction
      7. Drivers
    3. Rising Cases of Breast Cancer
      1. Increasing Rate of Pregnancy
        1. Unhygienic Barn Conditions Causing Contagious
    4. Mastitis in Bovines
      1. Restraints
    5. Lack of Awareness
    6. Complications in Diagnosis due to Similar Symptoms of Breast Cancer & Mastitis
      1. Opportunity
        1. Entering Developing Economies
      2. Macroeconomics
        1. Trends in Mastitis
      3. Porter’s Five Forces Model
        1. Bargaining Power of Suppliers
    7. Bargaining Power of Buyers
      1. Threat of New Entrants
        1. Threat of Substitutes
        2. Intensity of Rivalry
      2. Value Chain Analysis
        1. R&D & Designing
        2. Manufacturing
    8. Distribution & Sales
      1. Post-Sales Services
      2. Investment Opportunities
      3. Price Analysis
      4. Introduction
      5. Bovine
        1. Contagious Mastitis
        2. Environmental Mastitis
        3. Opportunist Mastitis
      6. Human
        1. Non-Infectious Mastitis
        2. Infectious Mastitis
      7. Introduction
      8. Bovine
        1. Antibiotics
        2. Vaccines
      9. Human
        1. Pain Relievers
        2. Antibiotics
    9. Global Mastitis Market, By End User
      1. Introduction
      2. Veterinary Centers
      3. Hospital & Clinics
      4. Introduction
      5. Americas
        1. North America
        2. South America
      6. Europe
        1. Western Europe
    10. Rest of Western Europe
      1. Eastern Europe
      2. Asia-Pacific
        1. Japan
        2. China
        3. India
        4. Australia
        5. South Korea
        6. Rest of Asia-Pacific
      3. Middle East & Africa
        1. Saudi Arabia
        2. United Arab Emirates
        3. Kuwait
        4. Oman
        5. Qatar
        6. Rest
    11. of Middle East
      1. Competitive Scenario
        1. Introduction
      2. Bayer AG
        1. Company Overview
        2. Financial Overview
        3. Products Offering
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategy
      3. BioNumerik Pharmaceuticals Inc
        1. Company Overview
        2. Financial Overview
        3. Products/Services Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategy
      4. Oncothyreon Inc
        1. Company Overview
        2. Financial Overview
        3. Products/Services Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategy
      5. Oncogenex
        1. Company Overview
        2. Financial Overview
        3. Products/Services Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategy
      6. Apthera Inc.
        1. Company Overview
        2. Financial Overview
        3. Products/Services Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategy
      7. Zoetis Inc
        1. Company Overview
        2. Financial Overview
        3. Products/Services Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategy
      8. Boehringer Ingelheim GmbH
        1. Company Overview
        2. Financial Overview
        3. Products/Services Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategy
      9. Merck Co. & Inc
        1. Company Overview
        2. Financial Overview
        3. Products/Services Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategy
    12. Astellas Pharma Inc
      1. Company Overview
        1. Financial Overview
        2. Products/Services Offered
        3. Key Developments
        4. SWOT Analysis
        5. Key Strategy
      2. Pfizer Inc.
        1. Company Overview
        2. Financial Overview
        3. Products/Services Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategy
      3. Novartis AG
        1. Company Overview
        2. Financial Overview
        3. Products/Services Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategy
      4. Sanofi SA
        1. Company Overview
        2. Financial Overview
        3. Products/Services Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategy
      5. F. Hoffmann-La Roche AG
        1. Company Overview
        2. Financial Overview
        3. Products/Services Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategy
      6. Discussion Blue Print
      7. References
    13. FOR BOVINE, BY TYPE 2020–2027 (USD MILLION)
    14. 2020–2027 (USD MILLION)
    15. (USD MILLION)
    16. MARKET FOR HUMAN, BY REGION 2020–2027 (USD MILLION)
    17. MASTITIS, BY REGION 2020–2027 (USD MILLION)
    18. BY REGION 2020–2027 (USD MILLION)
    19. (USD MILLION)
    20. GLOBAL MASTITIS MARKET FOR ANTIBIOTICS, BY REGION TYPE 2020–2027 (USD MILLION)
    21. GLOBAL MASTITIS MARKET FOR VACCINES, BY REGION 2020–2027 (USD MILLION)
    22. MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION)
    23. FOR PAIN RELIEVERS, BY REGION TYPE 2020–2027 (USD MILLION)
    24. FOR ANTIBIOTICS, BY REGION 2020–2027 (USD MILLION)
    25. 2020–2027 (USD MILLION)
    26. (USD MILLION)
    27. MARKET, BY REGION 2020–2027 (USD MILLION)
    28. (USD MILLION)
    29. MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION)
    30. (USD MILLION)
    31. AMERICAS MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION)
    32. AMERICAS MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION)
    33. MASTITIS MARKET, BY COUNTRY 2020–2027 (USD MILLION)
    34. (USD MILLION)
    35. NORTH AMERICA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION)
    36. MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION)
    37. MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION)
    38. MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION)
    39. MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION)
    40. BY TYPE 2020–2027 (USD MILLION)
    41. (USD MILLION)
    42. MARKET, BY TREATMENT 2020–2027 (USD MILLION)
    43. TYPE 2020–2027 (USD MILLION)
    44. 2020–2027 (USD MILLION)
    45. MILLION)
    46. FOR BOVINE, BY TYPE 2020–2027 (USD MILLION)
    47. 2020–2027 (USD MILLION)
    48. MILLION)
    49. CANADA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION)
    50. CANADA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION)
    51. MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION)
    52. BY TYPE 2020–2027 (USD MILLION)
    53. 2020–2027 (USD MILLION)
    54. (USD MILLION)
    55. EUROPE MASTITIS MARKET, BY REGION 2020–2027 (USD MILLION)
    56. BY TYPE 2020–2027 (USD MILLION)
    57. (USD MILLION)
    58. MARKET, BY TREATMENT 2020–2027 (USD MILLION)
    59. TYPE 2020–2027 (USD MILLION)
    60. TYPE 2020–2027 (USD MILLION)
    61. (USD MILLION)
    62. MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION)
    63. BY TYPE 2020–2027 (USD MILLION)
    64. 2020–2027 (USD MILLION)
    65. (USD MILLION)
    66. GERMANY MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION)
    67. FOR BOVINE, BY TYPE 2020–2027 (USD MILLION)
    68. 2020–2027 (USD MILLION)
    69. MILLION)
    70. GERMANY MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION)
    71. GERMANY MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION)
    72. MARKET, BY TYPE 2020–2027 (USD MILLION)
    73. 2020–2027 (USD MILLION)
    74. (USD MILLION)
    75. MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION)
    76. MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION)
    77. BY END–USER 2020–2027 (USD MILLION)
    78. (USD MILLION)
    79. MARKET FOR HUMAN, BY TYPE 2020&'

    Mastitis Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials